Adagio Medical's VT ablation PMA remains under FDA review as board explores strategic alternatives
The company reported no third-quarter revenue and $3.1 million in cash, and carried out a 1-for-30 reverse stock split to address Nasdaq's minimum bid price rule.
Adagio Medical Holdings reported its third-quarter 2026 results on 16 November, stating that the premarket approval (PMA) application for its vCLAS Ventricular Ablation System, intended for ventricular tachycardia, is still under review by the US Food and Drug Administration.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Adagio Medical Holdings, Inc. ↗
Article written by VigiEye from the official source (Adagio Medical Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.